Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sarepta Therapeutics (NQ: SRPT )

84.44 +3.16 (+3.89%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 1, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sarepta Therapeutics

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
The biggest pre-market stock movers for Friday are ready to go as we dive into the latest news for investors this morning! 
Via InvestorPlace
Why Sarepta Therapeutics Shares Are Trading Lower By Around 19%; Here Are 20 Stocks Moving Premarket
Gainers Enzo Biochem, Inc. (NYSE: ENZ) shares rose 89.9% to $2.26 in pre-market trading after the company announced it will sell its clinical laboratory to Labcorp. 
Via Benzinga
Nasdaq, S&P Futures Dip, Signaling Pause In Rally As Focus Shifts To Next Week's Fed Decision: Analyst Says Brace For More Volatility Near Term
The mood on Wall Street continues to be jittery, with the major index futures trading marginally to modestly lower. The weak sentiment reflected apprehensions concerning how the banking crisis will... 
Via Benzinga
The Latest Analyst Ratings for Sarepta Therapeutics
Via Benzinga
Novavax Stock Down On Concern Over Whether The Company Can Continue
Novavax warns that it may not be able to continue as a company. 
Via Talk Markets
Expert Ratings for Sarepta Therapeutics
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy. 
Via InvestorPlace
Meta Platforms To Rally 27%? Here Are 10 Other Analyst Forecasts For Thursday
Wells Fargo cut the price target for SVB Financial Group (NASDAQ: SIVB) from $350 to $300. Wells Fargo analyst Steven Shaw maintained an Overweight rating. SVB Financial shares fell 29.1% to $190.02 in... 
Via Benzinga
2 Biotech Stocks You Can Buy and Hold for the Next Decade
Regeneron and Sarepta Therapeutics have been on fire so far this year. 
Via The Motley Fool
Stock Market Rally Rebounds Despite Rising Yields; Salesforce, Tesla In Focus: Weekly Review
Many leaders flashed buy signals as the indexes rebounded from support. 
Via Investor's Business Daily
Why Sarepta Therapeutics' Shares Rose 23.4% This Week
The company's latest Duchenne muscular dystrophy gene therapy may have an accelerated approval. 
Via The Motley Fool
3 Best Growth Stocks to Buy In March
These three red-hot growth stocks have more room to run. 
Via The Motley Fool
Why Sarepta Therapeutics Stock Is Booming Today
Sarepta Therapeutics (NASDAQ: SRPT) shares are trading higher this Wednesday after the company reported better-than-expected fourth-quarter results. 
Via Benzinga
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Why This Sarepta Therapeutics Is Turning Bullish
Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) jumped in early trading on Wednesday, after the company reported an earnings beat for its fourth quarter. 
Via Benzinga
3D Systems, CarGurus, Sarepta Therapeutics And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded lower, with the Dow Jones dropping around 80 points on Wednesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
Sarepta Rockets And Breaks Out As FDA Smooths The Path For Its Gene Therapy
The FDA will not hold an advisory committee meeting for the company's gene therapy. 
Via Investor's Business Daily
Benzinga's Top Ratings Upgrades, Downgrades For March 1, 2023
Via Benzinga
Why Is Sarepta Therapeutics (SRPT) Stock Up 21% Today?
Sarepta Therapeutics (SRPT) stock is heading higher on Wednesday following the release of its latest earnings report and an upgrade. 
Via InvestorPlace
Investors Just Hit the Jackpot on These 2 Nasdaq Biotech Stocks
Markets are trying to rise, and these companies are helping out. 
Via The Motley Fool
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Sarepta Therapeutics To Rally Over 53%? Here Are 10 Other Analyst Forecasts For Wednesday
Keybanc raised the price target for Ambarella, Inc. (NASDAQ: AMBA) from $95 to $105. Keybanc analyst John Vinh maintained an Overweight rating. Ambarella shares fell 7.1% to $87.61 in pre-market... 
Via Benzinga
Why Reata Pharmaceuticals Shares Are Trading Higher By 140%; Here Are 20 Stocks Moving Premarket
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) rose 140.8% to $75.06 in pre-market trading after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
It's time to start the day with another breakdown of the biggest pre-market stock movers traders need to know about on Wednesday! 
Via InvestorPlace
Sarepta Therapeutics (SRPT) Q4 2022 Earnings Call Transcript
SRPT earnings call for the period ending December 31, 2022. 
Via The Motley Fool
12 Health Care Stocks Moving In Tuesday's After-Market Session
Via Benzinga
3 Gene Editing Stocks With the Best Long-Term Potential
These gene editing stocks are likely to deliver massive gains ahead in the fast-evolving biotech space 
Via InvestorPlace
Earnings Scheduled For February 28, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its fourth quarter. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.